Data-Driven Indication Expansion for TRPV1 Research Programs
In pharmaceutical research, maximizing the value of a therapeutic target often depends on identifying additional disease areas where it may provide clinical benefit. This case study demonstrates how Langate helped a pharmaceutical company expand its understanding of TRPV1 by combining biomedical data analysis with AI-assisted indication discovery.
Summary
Langate implemented an AI-enabled indication-discovery platform that enabled researchers to evaluate new disease opportunities for TRPV1-targeted therapies.
Quick Facts
- Timeline: 4 months
- Team: 6 specialists
- Output: 5 new disease indications identified
- 2 indications showed strong clinical potential and limited competition
- Supported strategic reallocation of R&D investment
Project Scope
The project covered data aggregation, development of an indication scoring model, dashboard creation, and deployment within the client's research environment. The platform was designed to support both scientific evaluation and portfolio planning activities.
Tech Stack
- Python
- TensorFlow
- Vertex AI
- Spotfire
Data sources: GWAS Catalog, OpenTargets, ClinicalTrials.gov, Pharmaproject, PubMed
The Client
The client is a pharmaceutical company developing therapies based on TRPV1 modulation. Their objective was to identify additional disease indications where TRPV1 could provide therapeutic value and support future research investments.
Business Requirements
- Discover new therapeutic opportunities for TRPV1
- Evaluate scientific and translational evidence consistently
- Reduce uncertainty in portfolio expansion decisions
- Improve efficiency of indication assessment
- Create a scalable methodology for future research programs
The Problem
The client lacked a structured framework for evaluating potential new indications. Researchers and strategists relied on manual reviews of scientific literature and disconnected data sources, making it difficult to assess which opportunities warranted further investment.
The Challenges
-
Managing large volumes of genetic, translational, and clinical data - Connecting scientific evidence with business priorities
- Ensuring transparency and traceability of recommendations
- Supporting collaboration between research and strategy teams
Problems Revealed
The project uncovered that potentially valuable indication opportunities remained hidden because evidence was distributed across multiple systems and datasets. Without a centralized analytical framework, prioritization decisions were often slower and less consistent than desired.
The Solution
Achievements
-
Identified 5 disease indications supported by scientific and translational evidence
-
Revealed 2 opportunities with favorable development characteristics
-
Enabled strategic reallocation of R&D resources
-
Reduced uncertainty in portfolio expansion planning
The platform helped the client move from fragmented indication research to a more systematic and evidence-based decision-making process.
Future Plans
-
The client is exploring the platform's use for additional targets and therapeutic areas.
-
Langate continues to support the expansion of AI-assisted portfolio planning capabilities across the organization's research pipeline.
Ready to Uncover New Indications for Your Project?
Send a message to Langate sales
